JP2006512906A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006512906A5 JP2006512906A5 JP2004540017A JP2004540017A JP2006512906A5 JP 2006512906 A5 JP2006512906 A5 JP 2006512906A5 JP 2004540017 A JP2004540017 A JP 2004540017A JP 2004540017 A JP2004540017 A JP 2004540017A JP 2006512906 A5 JP2006512906 A5 JP 2006512906A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- sirna
- shrna
- seq
- transcript
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004459 Small interfering RNA Proteins 0.000 claims description 144
- 210000004027 cell Anatomy 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 61
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 53
- 239000004055 small Interfering RNA Substances 0.000 claims description 51
- 241000712461 unidentified influenza virus Species 0.000 claims description 51
- 239000002773 nucleotide Substances 0.000 claims description 45
- 125000003729 nucleotide group Chemical group 0.000 claims description 45
- 241000700605 Viruses Species 0.000 claims description 38
- 108020004999 messenger RNA Proteins 0.000 claims description 38
- 208000015181 infectious disease Diseases 0.000 claims description 34
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 32
- 108091034135 Vault RNA Proteins 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 230000009368 gene silencing by RNA Effects 0.000 claims description 18
- 108091030071 RNAI Proteins 0.000 claims description 17
- 230000003612 virological effect Effects 0.000 claims description 17
- 241000894007 species Species 0.000 claims description 15
- 229920000642 polymer Polymers 0.000 claims description 14
- 229920006317 cationic polymer Polymers 0.000 claims description 13
- 230000000295 complement effect Effects 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 230000000692 anti-sense effect Effects 0.000 claims description 10
- 108020000999 Viral RNA Proteins 0.000 claims description 9
- 101710154606 Hemagglutinin Proteins 0.000 claims description 8
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 8
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 8
- 101710176177 Protein A56 Proteins 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 230000009385 viral infection Effects 0.000 claims description 8
- 239000000185 hemagglutinin Substances 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- -1 cationic lipid Chemical class 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 5
- 206010022000 influenza Diseases 0.000 claims description 5
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 5
- 230000035897 transcription Effects 0.000 claims description 5
- 241000712431 Influenza A virus Species 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 4
- 101710102873 Polymerase basic protein 2 Proteins 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 230000029812 viral genome replication Effects 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 239000012678 infectious agent Substances 0.000 claims 25
- 230000001939 inductive effect Effects 0.000 claims 16
- 238000000034 method Methods 0.000 claims 16
- 239000000126 substance Substances 0.000 claims 10
- 230000004048 modification Effects 0.000 claims 9
- 238000012986 modification Methods 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 108091081021 Sense strand Proteins 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 229940124447 delivery agent Drugs 0.000 claims 5
- 230000010076 replication Effects 0.000 claims 5
- 125000002091 cationic group Chemical group 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 4
- 210000002919 epithelial cell Anatomy 0.000 claims 4
- 230000000241 respiratory effect Effects 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 2
- 102000005348 Neuraminidase Human genes 0.000 claims 2
- 108010006232 Neuraminidase Proteins 0.000 claims 2
- 102100037516 Protein polybromo-1 Human genes 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 101710085035 RNA-directed RNA polymerase catalytic subunit Proteins 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 102000044158 nucleic acid binding protein Human genes 0.000 claims 2
- 108700020942 nucleic acid binding protein Proteins 0.000 claims 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims 1
- 101710159080 Aconitate hydratase A Proteins 0.000 claims 1
- 101710159078 Aconitate hydratase B Proteins 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 241000713196 Influenza B virus Species 0.000 claims 1
- 101710128560 Initiator protein NS1 Proteins 0.000 claims 1
- 102100034343 Integrase Human genes 0.000 claims 1
- 101710085938 Matrix protein Proteins 0.000 claims 1
- 101710127721 Membrane protein Proteins 0.000 claims 1
- 101710169959 Membrane protein 2 Proteins 0.000 claims 1
- 101710144127 Non-structural protein 1 Proteins 0.000 claims 1
- 101710144128 Non-structural protein 2 Proteins 0.000 claims 1
- 101710199667 Nuclear export protein Proteins 0.000 claims 1
- 229920002873 Polyethylenimine Polymers 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 102000014450 RNA Polymerase III Human genes 0.000 claims 1
- 108010078067 RNA Polymerase III Proteins 0.000 claims 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 claims 1
- 101710105008 RNA-binding protein Proteins 0.000 claims 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 210000001552 airway epithelial cell Anatomy 0.000 claims 1
- 229960003150 bupivacaine Drugs 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 229960003677 chloroquine Drugs 0.000 claims 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 238000002716 delivery method Methods 0.000 claims 1
- 239000005547 deoxyribonucleotide Substances 0.000 claims 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 230000009871 nonspecific binding Effects 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 230000007918 pathogenicity Effects 0.000 claims 1
- 108010011110 polyarginine Proteins 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229940063649 survanta Drugs 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 241001500351 Influenzavirus A Species 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 13
- 210000003501 vero cell Anatomy 0.000 description 12
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 8
- 238000010839 reverse transcription Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 102000007469 Actins Human genes 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41445702P | 2002-09-28 | 2002-09-28 | |
| US44637703P | 2003-02-10 | 2003-02-10 | |
| PCT/US2003/030502 WO2004028471A2 (en) | 2002-09-28 | 2003-09-29 | Influenza therapeutic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006512906A JP2006512906A (ja) | 2006-04-20 |
| JP2006512906A5 true JP2006512906A5 (https=) | 2009-07-30 |
Family
ID=32045286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004540017A Pending JP2006512906A (ja) | 2002-09-28 | 2003-09-29 | インフルエンザ治療剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050008617A1 (https=) |
| EP (1) | EP1658304A4 (https=) |
| JP (1) | JP2006512906A (https=) |
| KR (1) | KR20050084607A (https=) |
| AU (3) | AU2003279004B2 (https=) |
| CA (1) | CA2500468A1 (https=) |
| MX (1) | MXPA05003287A (https=) |
| NO (1) | NO20052058L (https=) |
| WO (2) | WO2004028471A2 (https=) |
Families Citing this family (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8541548B2 (en) * | 1999-06-07 | 2013-09-24 | Arrowhead Madison Inc. | Compounds and methods for reversible modification of biologically active molecules |
| US8137695B2 (en) * | 2006-08-18 | 2012-03-20 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
| US20080281041A1 (en) * | 1999-06-07 | 2008-11-13 | Rozema David B | Reversibly Masked Polymers |
| US8008355B2 (en) * | 2002-03-11 | 2011-08-30 | Roche Madison Inc. | Endosomolytic poly(vinyl ether) polymers |
| US8138383B2 (en) * | 2002-03-11 | 2012-03-20 | Arrowhead Madison Inc. | Membrane active heteropolymers |
| DE10214983A1 (de) * | 2002-04-04 | 2004-04-08 | TransMIT Gesellschaft für Technologietransfer mbH | Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen |
| US20080214437A1 (en) * | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| WO2004022003A2 (en) | 2002-09-06 | 2004-03-18 | University Of South Florida | Materials and methods for treatment of allergic diseases |
| US20060160759A1 (en) * | 2002-09-28 | 2006-07-20 | Jianzhu Chen | Influenza therapeutic |
| WO2006001810A2 (en) * | 2003-07-15 | 2006-01-05 | California Institute Of Technology | Improved inhibitor nucleic acids |
| WO2005017111A2 (en) * | 2003-07-15 | 2005-02-24 | The Trustees Of The University Of Pennsylvania | Methods and systems for identifying micro-rna targets and synthesizing novel micro-rnas and uses of the same |
| US20050256071A1 (en) * | 2003-07-15 | 2005-11-17 | California Institute Of Technology | Inhibitor nucleic acids |
| US20050060771A1 (en) * | 2003-09-11 | 2005-03-17 | Farmer Andrew Alan | siRNA encoding constructs and methods for using the same |
| AU2005227870A1 (en) * | 2004-02-17 | 2005-10-13 | University Of South Florida | Materials and methods for treatment of inflammatory and cell proliferation disorders |
| JP2007523159A (ja) * | 2004-02-20 | 2007-08-16 | ジェネシス リサーチ アンド デベロップメント コーポレイション リミテッド | Ｒｎａ干渉分子の標的送達 |
| WO2005110438A2 (en) * | 2004-04-15 | 2005-11-24 | Massachusetts Institute Of Technology | Methods and products related to the intracellular delivery of polysaccharides |
| US20050265927A1 (en) * | 2004-05-17 | 2005-12-01 | Yale University | Intranasal delivery of nucleic acid molecules |
| WO2006085987A2 (en) | 2004-07-09 | 2006-08-17 | University Of Iowa Research Foundation | Rna interference in respiratory epitheial cells |
| US20080222743A1 (en) * | 2004-08-25 | 2008-09-11 | Avigenics, Inc. | RNA interference and disease resistance in avians |
| US20090313712A1 (en) * | 2004-08-25 | 2009-12-17 | Leandro Christmann | RNA interference and disease resistance in avians |
| JP2008514202A (ja) | 2004-09-24 | 2008-05-08 | ニュークレオニクス・インコーポレイテッド | Ｒｎａｉによる一本鎖ウイルスの逆鎖複製中間体のターゲティング |
| US7592322B2 (en) * | 2004-10-22 | 2009-09-22 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
| US7790878B2 (en) | 2004-10-22 | 2010-09-07 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
| CA2586250A1 (en) * | 2004-11-05 | 2006-11-16 | Intradigm Corporation | Compositions for treating respiratory viral infections and their use |
| US8138327B2 (en) * | 2004-11-23 | 2012-03-20 | City Of Hope | Inducible systems and methods for controlling siRNA expression |
| NZ556097A (en) * | 2005-01-07 | 2009-12-24 | Alnylam Pharmaceuticals Inc | Rnai modulation of RSV and therapeutic uses thereof |
| WO2006113679A2 (en) | 2005-04-15 | 2006-10-26 | Board Of Regents, The University Of Texas System | Delivery of sirna by neutral lipid compositions |
| CA2596711C (en) | 2005-02-03 | 2015-12-15 | Benitec, Inc. | Rnai expression constructs |
| WO2006086345A2 (en) * | 2005-02-07 | 2006-08-17 | The Trustees Of Columbia University In The City Of New York | Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity |
| US8008468B2 (en) * | 2005-02-16 | 2011-08-30 | Benitec, Inc. | RNAi expression constructs with liver-specific enhancer/promoter |
| CA2603842A1 (en) * | 2005-04-08 | 2006-10-19 | Nastech Pharmaceutical Company Inc. | Rnai therapeutic for respiratory virus infection |
| US20070213293A1 (en) * | 2005-04-08 | 2007-09-13 | Nastech Pharmaceutical Company Inc. | Rnai therapeutic for respiratory virus infection |
| JP2008537752A (ja) * | 2005-04-12 | 2008-09-25 | イントラディグム コーポレイション | がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法 |
| CA2606429A1 (en) * | 2005-04-21 | 2006-11-02 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| WO2006116756A1 (en) * | 2005-04-28 | 2006-11-02 | Benitec, Limited. | Multiple-rnai expression cassettes for simultaneous delivery of rnai agents related to heterozygotic expression patterns |
| US7199109B2 (en) * | 2005-06-03 | 2007-04-03 | Cal Poly Pomona Foundation | Potent inhibition of influenza virus by specifically designed short interfering RNA |
| US20080184618A1 (en) * | 2005-08-03 | 2008-08-07 | Amcol International | Virus-Interacting Layered Phyllosilicates and Methods of Use |
| US20070031512A1 (en) * | 2005-08-03 | 2007-02-08 | Amcol International Corporation | Virus-interacting layered phyllosilicates and methods of inactivating viruses |
| US20100272769A1 (en) * | 2005-08-03 | 2010-10-28 | Amcol International | Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use |
| US20070099858A1 (en) * | 2005-10-03 | 2007-05-03 | Sirna Therapeutics, Inc. | RNA interference mediated of inhibition of influenza virus gene expression using short interfering nucleic acid (siNA) |
| KR20080061397A (ko) * | 2005-10-14 | 2008-07-02 | 나스텍 파마수티컬 컴퍼니 인코포레이티드 | Ｒｎａ 치료제용 펩티드 리보핵산 축합물 입자들의화합물들과 방법들 |
| EP2202239A1 (en) | 2005-11-01 | 2010-06-30 | Alnylam Pharmaceuticals Inc. | RNAI inhibition of influenza virus replication |
| CA2628113A1 (en) * | 2005-11-04 | 2007-05-18 | Nastech Pharmaceutical Company Inc. | Peptide-dicer substrate rna conjugates as delivery vehicles for sirna |
| WO2007056861A1 (en) * | 2005-11-18 | 2007-05-24 | Protiva Biotherapeutics, Inc. | Sirna silencing of influenza virus gene expression |
| CN100365122C (zh) * | 2005-12-30 | 2008-01-30 | 中国疾病预防控制中心病毒病预防控制所 | 针对乙型流感病毒多聚酶基因的siRNA序列及其应用 |
| CN100365123C (zh) * | 2005-12-30 | 2008-01-30 | 中国疾病预防控制中心病毒病预防控制所 | 针对乙型流感病毒膜蛋白基因的siRNA序列及其应用 |
| CN100365121C (zh) * | 2005-12-30 | 2008-01-30 | 中国疾病预防控制中心病毒病预防控制所 | 针对乙型流感病毒核壳蛋白基因的siRNA序列及其应用 |
| FI20060246A0 (fi) | 2006-03-16 | 2006-03-16 | Jukka Westermarck | Uusi kasvua stimuloiva proteiini ja sen käyttö |
| GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
| CA2656990A1 (en) * | 2006-04-28 | 2007-11-08 | University Of South Florida | Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor |
| DE602007013559D1 (de) * | 2006-07-07 | 2011-05-12 | Univ Aarhus | Nanoteilchen zur abgabe von nukleinsäure |
| GB0613753D0 (en) * | 2006-07-11 | 2006-08-23 | Norwegian Radium Hospital Res | Method |
| US9127293B2 (en) * | 2006-07-26 | 2015-09-08 | The University Of Chicago | Receptor-mediated delivery: compositions and methods |
| AU2007286059A1 (en) * | 2006-08-18 | 2008-02-21 | Mdrna, Inc. | Dicer substrate RNA peptide conjugates and methods for RNA therapeutics |
| US8017109B2 (en) * | 2006-08-18 | 2011-09-13 | Roche Madison Inc. | Endosomolytic poly(acrylate) polymers |
| FI20060751A0 (fi) | 2006-08-23 | 2006-08-23 | Valtion Teknillinen | Menetelmä prostatasyövän hoitoon ja mainitusta menetelmästä hyödyntävien potilaiden seulonta |
| WO2008022468A1 (en) * | 2006-08-24 | 2008-02-28 | British Columbia Cancer Agency Branch | Compositions and methods for treating myelosuppression |
| KR100817024B1 (ko) * | 2006-11-09 | 2008-03-26 | 재단법인 목암생명공학연구소 | 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물 |
| WO2008098139A2 (en) | 2007-02-07 | 2008-08-14 | The Regents Of The University Of Colorado | Axl tyrosine kinase inhibitors and methods of making and using the same |
| US20100015218A1 (en) * | 2007-02-16 | 2010-01-21 | Vasant Jadhav | Compositions and methods for potentiated activity of biologically active molecules |
| CA2680600A1 (en) | 2007-03-12 | 2008-09-18 | Antigen Express, Inc. | Li-rnai involved li suppression in cancer immunotherapy |
| EP2146575A4 (en) * | 2007-04-12 | 2010-11-24 | Alnylam Pharmaceuticals Inc | INFLUENZA POLYNUCLEOTIDES, EXPRESSION CONSTRUCTS, COMPOSITIONS AND METHOD FOR THEIR USE |
| CA2685127C (en) * | 2007-04-23 | 2019-01-08 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of rna interference agents |
| MX2009012317A (es) * | 2007-05-16 | 2010-04-01 | Mat Malta Advanced Technologie | Tratamiento y prevencion de influenza. |
| US8198256B2 (en) | 2007-07-03 | 2012-06-12 | Kyorin Pharmaceutical Co., Ltd. | Treatment of influenza |
| WO2009021325A1 (en) | 2007-08-10 | 2009-02-19 | British Columbia Cancer Agency Branch | Microrna compositions and methods for the treatment of myelogenous leukemia |
| CN101367750B (zh) | 2007-08-14 | 2012-05-23 | 中国人民解放军军事医学科学院毒物药物研究所 | (1s,2s,3s,4r)-3-[(1s)-1-乙酰氨-2-乙基-丁基]-4-胍基-2-羟基-环戊基-1-羧酸水合物及其医药用途 |
| AU2008334948B2 (en) * | 2007-12-13 | 2014-11-20 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for prevention or treatment of RSV infection |
| US20120230991A1 (en) * | 2008-07-29 | 2012-09-13 | Douglas Kim Graham | Methods and compounds for enhancing anti-cancer therapy |
| CA2746527A1 (en) | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| US20100168205A1 (en) * | 2008-10-23 | 2010-07-01 | Alnylam Pharmaceuticals, Inc. | Methods and Compositions for Prevention or Treatment of RSV Infection Using Modified Duplex RNA Molecules |
| HUE037082T2 (hu) * | 2008-11-10 | 2018-08-28 | Arbutus Biopharma Corp | Új lipidek és készítmények terápiás hatóanyagok szállítására |
| US20100291188A1 (en) * | 2008-12-04 | 2010-11-18 | Musc Foundation For Research Development | Periostin Inhibitory Compositions for Myocardial Regeneration, Methods of Delivery, and Methods of Using Same |
| US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
| US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| EP2406379A4 (en) * | 2009-03-13 | 2012-09-26 | Egen Inc | COMPOSITIONS AND METHODS FOR RELEASING BIOLOGICALLY ACTIVE RNA |
| FI20090161A0 (fi) | 2009-04-22 | 2009-04-22 | Faron Pharmaceuticals Oy | Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä |
| PE20121118A1 (es) | 2009-05-12 | 2012-09-05 | Romark Lab Lc | Compuestos de haloalquil heteroaril benzamida |
| AP2012006064A0 (en) * | 2009-06-26 | 2012-02-29 | Romark Lab Lc | Compounds and methods for treating influenza. |
| DE102009031274A1 (de) | 2009-06-30 | 2011-01-13 | Justus-Liebig-Universität Giessen | Liposomen zur pulmonalen Applikation |
| WO2011035322A2 (en) * | 2009-09-21 | 2011-03-24 | Intelligent Medical Devices, Inc. | Optimized probes and primers and methods of using same for the binding, detection, differentiation, isolation and sequencing of influenza a; influenza b; 2009 inlfuenza a/h1n1; and a 2009 influenza a/h1n1 rna sequence mutation associated with oseltamivir resistance |
| US20130079382A1 (en) | 2009-10-12 | 2013-03-28 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro |
| EP3000885B1 (en) | 2009-12-18 | 2018-07-25 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
| JP2013519869A (ja) | 2010-02-10 | 2013-05-30 | ノバルティス アーゲー | 筋肉成長のための方法および化合物 |
| DK2539451T3 (da) * | 2010-02-24 | 2016-04-04 | Arrowhead Res Corp | Sammensætninger til målrettet tilførsel af siRNA |
| HRP20182039T1 (hr) | 2010-04-23 | 2019-02-08 | Cold Spring Harbor Laboratory | NOVE STRUKTURNO DIZAJNIRANE MOLEKULE shRNA |
| CA3098080A1 (en) | 2010-04-23 | 2011-10-27 | Arrowhead Research Corporation | Organic compositions to treat beta-enac-related diseases |
| US20120244209A1 (en) | 2011-03-02 | 2012-09-27 | Roth Jack A | Tusc2 therapies |
| US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
| FI20115640A0 (fi) | 2011-06-22 | 2011-06-22 | Turun Yliopisto | Yhdistelmähoito |
| CN103930547A (zh) | 2011-09-02 | 2014-07-16 | 诺华股份有限公司 | 用于治疗hsf1相关疾病的有机组合物 |
| FI20115876A0 (fi) | 2011-09-06 | 2011-09-06 | Turun Yliopisto | Yhdistelmähoito |
| EP2591770B1 (en) * | 2011-11-14 | 2016-03-16 | Silenseed Ltd | Compositions for siRNA delivery and methods of manufacturing and using same |
| CA2860228A1 (en) * | 2011-12-23 | 2013-06-27 | Egen, Inc. | Compositions and methods for the delivery of biologically active rnas |
| CA2860676A1 (en) | 2012-01-09 | 2013-07-18 | Novartis Ag | Organic compositions to treat beta-catenin-related diseases |
| EP3272868A1 (en) | 2012-05-02 | 2018-01-24 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat kras-related diseases |
| WO2014011512A1 (en) * | 2012-07-08 | 2014-01-16 | Sirnaomics, Inc. | Compositions and methods for "resistance-proof" sirna therapeutics for influenza |
| DK2872631T3 (en) | 2012-07-13 | 2017-06-12 | Turun Yliopisto | COMBINATION THERAPY |
| CN103565745A (zh) | 2012-08-10 | 2014-02-12 | 德克萨斯州大学系统董事会 | 用于治疗中风的神经保护性脂质体组合物和方法 |
| US9801953B2 (en) | 2012-10-15 | 2017-10-31 | Emory University | Nanoparticles carrying nucleic acid cassettes for expressing RNA |
| SG10201706960TA (en) | 2013-02-28 | 2017-10-30 | Arrowhead Res Corp | Organic compositions to treat epas1-related diseases |
| US9693958B2 (en) | 2013-03-15 | 2017-07-04 | Cureport, Inc. | Methods and devices for preparation of lipid nanoparticles |
| WO2015051135A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Organic compositions to treat hepcidin-related diseases |
| EP3736334A1 (en) | 2014-07-16 | 2020-11-11 | Arrowhead Pharmaceuticals, Inc. | Rnai compositions to treat apoc3-related diseases |
| EP3191592A1 (en) | 2014-09-11 | 2017-07-19 | Novartis AG | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
| WO2016065282A1 (en) * | 2014-10-24 | 2016-04-28 | The Regents Of The University Of Michigan | Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels |
| EP3227446A1 (en) | 2014-12-01 | 2017-10-11 | Novartis AG | Compositions and methods for diagnosis and treatment of prostate cancer |
| EP3302525A2 (en) | 2015-06-05 | 2018-04-11 | Novartis AG | Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders |
| US9856481B2 (en) | 2015-08-13 | 2018-01-02 | Ann & Robert H. Lurie Children's Hospital | MicroRNA treatment of fibrosis |
| US10736880B2 (en) | 2015-12-18 | 2020-08-11 | The Board Of Regents Of The University Of Texas Systems | Therapeutics for preterm labor management |
| KR101712856B1 (ko) * | 2016-06-16 | 2017-03-07 | 재단법인 한국파스퇴르연구소 | 인플루엔자 바이러스의 복제에 관여하는 신규 인간 유전자 및 이의 용도 |
| WO2018047148A1 (en) | 2016-09-12 | 2018-03-15 | Novartis Ag | Compounds for the inhibition of mirna |
| CN110072540B (zh) | 2016-10-12 | 2023-06-02 | 得克萨斯州大学系统董事会 | 用于tusc2免疫治疗的方法和组合物 |
| US20180245065A1 (en) | 2016-11-01 | 2018-08-30 | Novartis Ag | Methods and compositions for enhancing gene editing |
| WO2018195355A1 (en) | 2017-04-19 | 2018-10-25 | Rxi Pharmaceuticals Corporation | Topical delivery of nucleic acid compounds |
| US11530413B2 (en) | 2017-07-21 | 2022-12-20 | Novartis Ag | Compositions and methods to treat cancer |
| US10597657B2 (en) | 2017-09-11 | 2020-03-24 | Arrowhead Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) |
| CA3084821A1 (en) | 2017-12-15 | 2019-06-20 | Board Of Regents, The University Of Texas System | Methods and compositions for treating cancer using exosomes-associated gene editing |
| WO2019150309A1 (en) | 2018-02-02 | 2019-08-08 | Hammack Scott | Modulators of gpr68 and uses thereof for treating and preventing diseases |
| EP3775258A4 (en) | 2018-03-28 | 2022-01-26 | Board of Regents, The University of Texas System | IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES |
| EP3788138A1 (en) | 2018-05-02 | 2021-03-10 | Novartis AG | Regulators of human pluripotent stem cells and uses thereof |
| WO2020086701A1 (en) | 2018-10-24 | 2020-04-30 | Codiak Biosciences, Inc. | Methods to improve potency of electroporation |
| SG11202105577TA (en) | 2019-01-09 | 2021-06-29 | Arrowhead Pharmaceuticals Inc | Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use |
| JP2022519718A (ja) | 2019-02-08 | 2022-03-24 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 加齢および加齢性臓器不全に関連する疾患の処置のためのテロメラーゼ含有エキソソーム |
| WO2021160937A1 (en) | 2020-02-11 | 2021-08-19 | Turun Yliopisto | Therapy of ras-dependent cancers |
| WO2021211923A1 (en) * | 2020-04-16 | 2021-10-21 | Pulmoquine Therapeutics, Inc. | Compositions and methods for treating disease |
| EP4138791A1 (en) | 2020-04-20 | 2023-03-01 | Board of Regents, The University of Texas System | Biologically active dry powder compositions and method of their manufacture and use |
| WO2021236852A1 (en) | 2020-05-20 | 2021-11-25 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
| WO2022040435A1 (en) | 2020-08-19 | 2022-02-24 | The Board Of Regents Of The University Of Texas System | Nanodrugs for targeted drug delivery and use thereof |
| US20230303665A1 (en) | 2020-08-28 | 2023-09-28 | Sana Biotechnology, Inc. | Modified anti-viral binding agents |
| WO2022155500A1 (en) | 2021-01-14 | 2022-07-21 | Senti Biosciences, Inc. | Secretable payload regulation |
| EP4526455A1 (en) | 2022-05-18 | 2025-03-26 | The Children's Hospital of Philadelphia | Compositions and methods for inducible alternative splicing regulation of gene expression |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194428A (en) * | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
| US20020165183A1 (en) * | 1999-11-29 | 2002-11-07 | Hans Herweijer | Methods for genetic immunization |
| DE19960206A1 (de) * | 1999-12-14 | 2001-07-19 | Frank Czubayko | Komplexierung von RNS mit Polyethyleniminen zur deren Stabilisierung und zellulären Einschleusung |
| PT1309726E (pt) * | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| EP1339423A2 (en) * | 2000-05-24 | 2003-09-03 | University of Massachusetts | Intraflagellar transport |
| US20020061861A1 (en) * | 2000-08-17 | 2002-05-23 | Hans Herweijer | Nucleic acid expression from linear nucleic acids |
| US20020081736A1 (en) * | 2000-11-03 | 2002-06-27 | Conroy Susan E. | Nucleic acid delivery |
| US20040259247A1 (en) * | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| WO2003008628A2 (en) * | 2001-07-20 | 2003-01-30 | Ribozyme Pharmacuticals, Inc. | Enzymatic nucleic acid peptide conjugates |
| US7101995B2 (en) * | 2001-08-27 | 2006-09-05 | Mirus Bio Corporation | Compositions and processes using siRNA, amphipathic compounds and polycations |
| US20040162235A1 (en) * | 2003-02-18 | 2004-08-19 | Trubetskoy Vladimir S. | Delivery of siRNA to cells using polyampholytes |
-
2003
- 2003-09-29 MX MXPA05003287A patent/MXPA05003287A/es not_active Application Discontinuation
- 2003-09-29 AU AU2003279004A patent/AU2003279004B2/en not_active Withdrawn - After Issue
- 2003-09-29 CA CA002500468A patent/CA2500468A1/en not_active Abandoned
- 2003-09-29 US US10/674,087 patent/US20050008617A1/en not_active Abandoned
- 2003-09-29 WO PCT/US2003/030502 patent/WO2004028471A2/en not_active Ceased
- 2003-09-29 KR KR1020057005369A patent/KR20050084607A/ko not_active Abandoned
- 2003-09-29 EP EP03770515A patent/EP1658304A4/en not_active Withdrawn
- 2003-09-29 JP JP2004540017A patent/JP2006512906A/ja active Pending
- 2003-09-29 AU AU2003279010A patent/AU2003279010A1/en not_active Abandoned
- 2003-09-29 WO PCT/US2003/030508 patent/WO2004029213A2/en not_active Ceased
-
2005
- 2005-04-27 NO NO20052058A patent/NO20052058L/no not_active Application Discontinuation
-
2010
- 2010-06-30 AU AU2010202770A patent/AU2010202770A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006512906A5 (https=) | ||
| JP2006512906A (ja) | インフルエンザ治療剤 | |
| Ge et al. | Use of siRNAs to prevent and treat influenza virus infection | |
| Thomas et al. | Non-viral siRNA delivery to the lung | |
| EP2295543A1 (en) | Method for the preparation of an influenza virus | |
| US20040242518A1 (en) | Influenza therapeutic | |
| US20070213293A1 (en) | Rnai therapeutic for respiratory virus infection | |
| US8691781B2 (en) | Compositions for treating respiratory viral infections and their use | |
| US20100204297A1 (en) | Influenza therapeutic | |
| WO2007142792A2 (en) | Potent inhibition of influenza virus by specifically designed short interfering rna | |
| Zhou et al. | RNA interference of avian influenza virus H5N1 by inhibiting viral mRNA with siRNA expression plasmids | |
| CN101880677B (zh) | 针对2009新甲型流感病毒多聚酶基因和核蛋白基因的siRNA序列及其应用 | |
| US9868952B2 (en) | Compositions and methods for “resistance-proof” SiRNA therapeutics for influenza | |
| JP6286050B2 (ja) | トリインフルエンザウイルスのｍｉＲＮＡとその同定、検出および使用 | |
| JP2008533990A (ja) | インフルエンザ治療剤 | |
| CN1968959B (zh) | 用于抑制流行性感冒病毒感染的短干扰rna、短发夹rna及编码它们的载体，相关组合物及其应用 | |
| Švancarová et al. | Induction of interferon lambda in influenza a virus infected cells treated with shRNAs against M1 transcript | |
| WO2022159383A1 (en) | Engineered nucleic acids targeting long noncoding rna involved in pathogenic infection | |
| TW202545542A (zh) | 預防或治療流感的組成物及方法 | |
| JP2009526516A (ja) | 呼吸性ウイルス感染を処置するための組成物およびその使用 | |
| HK1104302B (en) | Short interfering rna, short hairpin rna and coding vectors thereof, related compositions and use thereof used for inhibiting influenza virus infection | |
| WO2008089265A2 (en) | Anti-viral methods and compositions |